Articles tagged with Drug Combinations
Researchers analyzed 101 Chinese AML samples and identified three subtypes with different molecular characteristics and clinical outcomes. The study also found potential drug combinations that could improve treatment efficacy for subtype S-II&III patients who benefited from allogenic haematopoietic stem cell transplantation.
A phase 2 study found that the combination of belzutifan and cabozantinib produced a confirmed objective response rate of 70% among patients with advanced clear-cell renal cell carcinoma. The treatment was well-tolerated, with manageable serious adverse events.
Researchers discovered that the protein PIN1 drives bladder cancer by triggering cholesterol synthesis, which fuels out-of-control cell growth. A combination of statins and a PIN1 inhibitor effectively blocks tumor growth in mice, offering a promising therapeutic approach for this deadly disease.
A novel drug combination of albendazole and ivermectin demonstrates superior efficacy in treating Trichuris trichiura and other soil-transmitted helminths. The treatment has shown safety in a phase II-III trial, potentially aiding endemic countries in meeting the WHO's Roadmap for Neglected Tropical Diseases.
A team of researchers at USC will receive funding to test a novel approach to slowing age-related cognitive decline, targeting the brain's lymphatic system. The grant aims to delay the onset of Alzheimer's and Parkinson's disease by clearing waste buildup.
Adding camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response in patients with early or locally advanced triple-negative breast cancer. The treatment showed substantial benefits, leading researchers to explore its potential as a neoadjuvant strategy.
Researchers found that a new chemotherapy regimen, eBEACOPDac, resulted in fewer and less severe side effects compared to the existing regimen, eBEACOPP. Patients treated with eBEACOPDac experienced improved fertility recovery and reduced hospital time, making it a potential game-changer for treating Hodgkin lymphoma.
A Virginia Tech researcher has received a collaborative grant to improve cancer therapies by developing 3D liver organoids and employing cutting-edge microscopy technology. The project aims to identify the most effective treatments for cancer, enabling better-targeted treatments.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
A clinical trial found that combining two commonly recommended medications into a single pill lowered blood pressure and was safe among Indian adults. The study's results have significant meaning for South Asian adults, including those living in the US.
A new combination of immunotherapy and epigenetic drug may transform resistant pancreatic tumors into susceptible ones, according to a study by Johns Hopkins Medicine researchers. The treatment showed promise in a subset of patients, with tumor shrinkage and durable responses observed over several months.
A $3.96 million grant will support the development of a monitoring device and data-processing algorithm to guide combination therapy design against multidrug-resistant bacteria. The goal is to overcome bacterial defenses and combat the emergence of resistance.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
A new research project will test a combination of two targeted therapies, teclistamab and daratumumab, to treat AL amyloidosis, a rare disease affecting approximately 4,500 people annually in the U.S. The study aims to leverage previous findings from multiple myeloma to expand understanding of this treatment option.
The ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present several abstracts at the 66th American Society of Hematology Meeting & Exposition. Promising results from a phase 2 study in acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial show improved outcomes for patients with B-cell acute lymphobla...
A new study by MUSC researchers reveals how cancer cells develop resistance to hydroxychloroquine, an anti-malarial drug repurposed for cancer therapy. The findings suggest that targeting specific metabolic and export pathways can prevent resistance, opening the door for novel combination therapies.
A phase 2 clinical trial found that the combination of vidutolimod and nivolumab led to tumor control in 55% of patients, with higher levels of immune-related proteins detected in responders. The study also uncovered unique signatures of TLR9 activation and a link between gut microbiome and response to therapy.
A remarkable clinical and metabolic response is reported in a metastatic BRAF V600E-mutated glomangiosarcoma treated with encorafenib and binimetinib. The combination of BRAF and MEK inhibitors achieves a long-lasting complete morpho-metabolic response in the patient.
A clinical trial suggests that tucatinib and trastuzumab may benefit patients with rare bile duct cancer who also have HER2-mutated breast cancer. The treatment combination showed a 46.7% objective response rate in patients with bile duct cancer, compared to 22.2% in the broader patient group.
A large federally funded study found a 37% reduction in overdose deaths from opioids combined with stimulant drugs other than cocaine, primarily fentanyl and methamphetamine. Intervention communities implemented evidence-based practices, including naloxone distribution and education campaigns, which led to lower death rates.
Researchers at VCU Massey Comprehensive Cancer Center are exploring a new approach to treating liver cancer using immunotherapy and a newly developed drug that inhibits the MYC gene. The four-year grant aims to identify effective treatment combinations for hepatocellular carcinoma, improving patient survival rates.
Researchers at Rice University have developed a time-release technology called PULSED that could help protect against poliomyelitis in combination vaccines. The technology would allow poliovirus-like particles to be released from microparticles after a few days, ensuring full vaccination efficacy.
A new study found that 5-fluorouracil kills cells by interfering with RNA synthesis, not DNA damage. The findings suggest that combining 5-FU with drugs affecting RNA synthesis could make it more effective in patients with gastrointestinal cancers.
Researchers developed a mathematical model predicting enhanced survival outcomes for NSCLC patients with novel treatment combinations. The model neutralizes the negative effects of miR-155, boosting standard-of-care treatments like cisplatin and immune checkpoint inhibitors.
Researchers have tested a combination of treatments in mice with lung cancer and shown that these allow immunotherapies to target non-responsive tumours. The combination therapy allows 'immune cold' tumours to respond to the body's own defences.
The CheckMate 067 trial showed that combining nivolumab and ipilimumab improved outcomes for metastatic melanoma patients, with a median survival time over six years. Long-term follow-up found no new safety signals for the treatment, and metastatic melanoma survivors become increasingly likely to die of other causes as they age.
Prescription volumes for stimulant and antidepressant medications rose, while opioid volumes decreased between 2019 and 2022. Telehealth prescriptions climbed across medications, with a notable increase in opioids.
A study by UT Health San Antonio urologist Ronald Rodriguez found that combining valproic acid, an anti-seizure medication, with DHA, a type of omega-3 fatty acid, may reduce the risk of contracting COVID-19 and lessen its severity. The combination has been shown to activate ancient antiviral pathways against coronaviruses.
Research found that combining neonicotinoids with fungicides significantly increased mortality of bee larvae, while also affecting adult honeybee survival rates and lifespan. The study suggests that solitary wild bees may be more vulnerable to pesticide effects due to their smaller colony size.
Researchers found that omitting the bolus-specific 5-fluorouracil (5-FU) portion from common chemotherapy regimens improves tolerability without sacrificing treatment effectiveness. The study of 11,765 patients shows no decrease in overall survival but a notable reduction in cytopenias.
A new study reveals that young patients treated with psychiatric medications receive potentially dangerous combinations at a concerning frequency. Researchers analyzed New York State Medicaid records for over 141,000 patients and found nearly 400 received at least one potentially dangerous combination for one month or longer.
A major review by the Cochrane Tobacco Addiction Group identifies three effective ways to stop smoking: counseling, bupropion, and nicotine replacement therapy. The study found that combining these strategies with behavioral support yields the best results for quitting smoking.
Researchers at ETH Zurich have developed a new method to produce billions of pharmaceutically active substances using DNA-encoded chemical libraries. The new method can synthesize and test much larger drug molecules, including ring-shaped peptides, and reduces contamination in the molecular library.
Researchers found that digital consultations significantly improved medication adherence among heart failure patients, with 28% receiving optimal medication combinations after 12 weeks. The study also showed no negative impact on patient satisfaction or quality of life.
A novel low-dose 3-in-1 blood pressure pill (GMRx2) significantly reduces blood pressure in patients with uncontrolled hypertension. After six months treatment, the GMRx2 group achieved a 5.8mmHg lower systolic blood pressure compared to standard care.
Researchers developed a new tool to track immune health patterns over time, revealing how checkpoint inhibitor therapies work together to recruit new T cells. The study found that the combination therapy produces waves of new T cells with each dose, rather than continually strengthening existing ones.
Researchers have developed a novel nanoparticle drug-delivery system to activate an immune pathway in combination with tumor-targeting agents, showing promising results in treating pancreatic cancer. Eight out of nine mice tested experienced tumor improvements, including two complete responses.
A WVU researcher argues that more validation is needed for the increasing number of gallbladder surgeries performed for biliary dyskinesia, a functional gallbladder disorder. The researcher suggests that a combination of factors must come together to diagnose and select patients who would benefit from surgery.
Researchers uncovered how combining immunotherapies targeting PD1 and LAG3 enhances CD8+ T cell responses, leading to improved cancer-killing prowess and enhanced survival rates. The studies also revealed that relatlimab is not inert and can be combined with other immunotherapies to improve responses.
Researchers highlight the need to develop new anti-angiogenic agents to improve cancer treatment efficacy, citing knowledge gaps in human clinical trials. The review recommends considering tumor mutations, microenvironment, and patient profiles to select optimal AAD combinations.
Uncontrolled hypertension is a leading cause of premature death and disability worldwide, with 54% of patients aware but only 21% actively controlled. Effective treatment requires lifestyle changes and medication, as well as regular blood pressure monitoring to adjust doses accordingly.
Researchers developed a new approach to combat cancer by hyperactivating tumor cells, making them stressed and vulnerable to specific drugs. The combination strategy showed promising results in colorectal and pancreatic adenocarcinoma models, paving the way for potential treatment options.
Researchers at the Mayo Clinic Comprehensive Cancer Center discovered a new treatment approach that improved survival rates for patients with B-cell precursor leukemia by nearly 60%. The study found that adding blinatumomab to chemotherapy reduced the risk of leukemia recurrence and death.
A phase II clinical trial found that combining sEphB4-HSA with pembrolizumab improved outcomes in HPV-negative, EphrinB2-positive head and neck squamous cell carcinoma patients. The combination showed a favorable toxicity profile and activity, particularly among those with HNSCC.
The nirmatrelvir/ritonavir regimen has shown promise in reducing COVID-19 hospitalizations and potentially lowering all-cause mortality. However, the evidence is limited and varied, with real-world studies showing a high level of variability due to differences in patient characteristics and care practices.
A new combined cell therapy for kidney transplants uses a combination of bone marrow cells from the donor and Treg cells from the recipient to reduce the donor-specific reaction. This approach preserves the overall diversity of the T-cell receptor repertoire, crucial for immune defence.
A combination treatment incorporating three drugs – tamsulosin, metoprolol, and bromocriptine – significantly slowed disease progression in four different animal models of IRD. The study suggests that drug repurposing could provide solutions for rare diseases like retinal degenerations, which are currently inaccessible therapeutically.
A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.
Researchers discuss the use of antibody-drug conjugates (ADCs) in treating biologically aggressive tumors, such as uterine serous carcinoma. The ADC T-DXd has shown remarkable preclinical activity against primary USC cells lines and xenografts overexpressing HER2/neu.
Researchers will combine patients' self-reports with mobile app, wearable device, genetic sample, and clinical record data to predict which approaches will work best for an individual. The goal is to improve the success of first-time mental health treatment.
Researchers found that regorafenib synergizes with TAS102 to inhibit cancer growth, angiogenesis, and microvessel density in preclinical models of colorectal and gastric cancers. The combination also suppresses ERK1/2 activation regardless of KRAS or BRAF mutational status.
Researchers found that combining sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists reduces the risk of major adverse cardiovascular events and chronic kidney disease progression by 11% and 33%, respectively. The study suggests using this combination to further improve outcomes in patients with typ...
Scientists are conducting a clinical trial to explore the use of anti-retroviral medications Ritonavir and Lopinavir as a potential treatment for brain tumors in patients with Neurofibromatosis 2. The study aims to determine if these drugs can help reduce tumor growth and survival in NF2 patients.
A new trial indicates that immunotherapy could successfully treat the most common form of colorectal cancer. The study, published in Nature Medicine, found that botensilimab and balstilimab caused tumours to shrink or remain stable in 61% of patients with microsatellite stable metastatic colorectal cancer.
A new study led by researchers at UC San Francisco found that a virtual emotion-centered program called TunedIn can reduce diabetes distress by half and improve glucose control. The program incorporates elements of Acceptance and Commitment Therapy and was delivered virtually to 276 adults with Type 1 diabetes.
A clinical trial shows that a combination of injectable naltrexone and extended-release oral bupropion reduces methamphetamine use for up to 12 weeks. The study found a significant increase in methamphetamine-negative urine tests among participants receiving the two-drug therapy.
A new study combines bisphosphonates, commonly used for osteoporosis, with azole antifungals to treat fungal infections. The combination effectively targets dermatophytes and prevents resistance development.
A new study found that combining histone deacetylase inhibitors, poly (ADP ribose) polymerase inhibitors, and decitabine resulted in synergistic cytotoxicity in all cell lines tested. This combination impaired DNA repair pathways and altered epigenetic regulation of gene expression.
A combination of amivantamab and lazertinib shows benefits over standard treatment in a subgroup of patients with advanced lung cancer, particularly those with poor prognostic markers. The new therapeutic strategy reduced the risk of disease progression and death by 30% compared to osimertinib.
Researchers at Dana-Farber Cancer Institute have reported encouraging results from three separate studies on treatments for central nervous system lymphoma, breast cancer, and glioblastoma. CAR T-cell therapy showed a 94% overall response rate in patients with CNS lymphoma, while an antibody-drug conjugate plus checkpoint inhibitor imp...